News

Ahead of sessions kicking off on February 25, the ACTRIMS committee offered a look into what data, plenary talks, and developments are set to be presented at the upcoming ACTRIMS Forum 2021.

Similar proportions of both in-clinic and telemedicine patients had modified Rankin scale score improvements.

The global head of Development and External Affairs-Neuroscience at Janssen Pharmaceutical provided his expectations for the upcoming ACTRIMS Forum.

The director and founder of the Sleep Centers of Middle Tennessee compared the integrated care model of ISPs to the transactional model of DMEs.

The duo from Cleveland Clinic discussed their recently initiated study which will evaluate the neuroprotective features of home-based intervention in high-risk individuals for Alzheimer disease.

The director of Neurology and the Memory and Aging Program at Butler Hospital and principal investigator in the aducanumab clinical trial program discussed the investigational agent and the current landscape of care.

The assistant professor of pediatric neurology at the Washington University in St. Louis spoke to the insights of a recent survey she and colleagues conducted.

A recent study investigated self-reported outcomes of preventive treatment prior to the introduction of calcitonin gene related peptide (CGRP) receptor targeting.

Factors such as previous emergency department visits, hypertension, and tobacco use disorder were related to future migraine-related emergency department visits.

The assistant professor of neurology at Thomas Jefferson University gave background on what other studies have observed brain implants for poststroke patients and how they differ from his work.

A pair of migraine experts explores several topics in the acute treatment of migraine, including recent therapeutic innovations.

Siponimod (Mayzent; Novartis) improved Symbol Digit Modalities Test scores in patients at 12, 18, and 24 months compared to placebo.

The director of the Montefiore Headache Center discussed how rimegepant has certain benefits over monoclonal antibodies, such as a much shorter half-life.

Investigators noted that empirical work is needed to determine if change from baseline, fixed time point assessments, and responder definitions, or other approaches optimize power and sensitivity to change.

Despite 2020 being a challenging year for those in medicine, the epilepsy therapeutic space featured a number of key steps forward.

Here's what is coming soon to NeurologyLive.

Bijan Nejadnik, MD, chief medical officer, SanBio, also thanked neurological experts that collaborated on the phase 2 STEMTRA trial.

Big data is on the precipice of revolutionizing multiple sclerosis knowledge and treatment.

Researchers also found that during the COVID-19 pandemic, there were reduced rates of stroke quality of care measures.

The chief scientific officer of the Parkinson’s Foundation discussed the importance of screening for mood disturbances in patients with PD.

The PACAP pathway has shown promise as a potential novel therapeutic target in the treatment of migraine.

The director of the Massachusetts General Hospital ALS Care Center discussed some of the biggest challenges for patients with ALS and what should be prioritized in research.

The breakthrough designation gives BrainQ access to the new Medicare Coverage of Innovative Technology pathway.

Neurology News Network for the week ending February 20, 2021.

Racial disparities in biomarkers highlight the need to investigate different populations in trials of Alzheimer disease.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending February 19, 2021.

Masahito Kawabori, MD, PhD, associate professor, Hokkaido University, discussed results of the phase 2 STEMTRA trial.

The founder and director of the Sleep Centers of Middle Tennessee discussed how patients that better understand the benefits of PAP therapy had better adherence to the therapy.

Surgical treatment for epilepsy has been proven its effectiveness, and preoperative evaluation has sparked a debate: to spare or not to spare the hippocampus?

Overall, variants within known ALS-linked genes are of potential clinical importance for 42% of patients, according to the study authors.